Ajay Chaudhuri, MD
Endocrinology, Diabetes & Metabolism · Buffalo, NYNPI 1386631851
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $736,010 of the $887,550 with a category attached, or 82.9%. Lilly USA, LLC accounts for 69.9% of it on its own, with 13 other manufacturers making up the rest. Among endocrinology, diabetes & metabolism clinicians in NY with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 1,171 payments — averaging $757.94 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Lilly USA, LLC$620K
- Novo Nordisk$187K
- Eli Lilly$20K
- AstraZeneca$19K
- Sanofi-aventis U.S. LLC$18K
- Boehringer Ingelheim$7K
- plus $17K from 8 others
Across 145 payments — averaging $10,634 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Eli Lilly$1.1M
- AbbVie$246K
- Intercept Pharmaceuticals, Inc.$42K
- AstraZeneca$30K
- GSK$28K
- Bausch Health US, LLC$26K
- plus $40K from 3 others
What the payments were for
- Consulting fees$55,0536%
- Speaking & faculty fees$736,01083%
- Travel & lodging$80,2699%
- Food & beverage$16,1312%
- Education$870%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Lilly USA, LLC | 859 | $619,967 |
| Novo Nordisk | 186 | $186,632 |
| Eli Lilly | 18 | $19,963 |
| AstraZeneca | 33 | $19,132 |
| Sanofi-aventis U.S. LLC | 22 | $18,328 |
| Boehringer Ingelheim | 18 | $6,885 |
| Merck | 7 | $5,578 |
| Bayer | 12 | $5,054 |
| Amgen(2 entities) | 6 | $2,648 |
| Bigfoot Biomedical Inc | 2 | $2,600 |
| Medtronic(2 entities) | 3 | $394 |
| Corcept Therapeutics | 3 | $238 |
| Tandem Diabetes Care, Inc. | 1 | $117 |
| Dexcom, Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- MOUNJARO$306,952
- TRULICITY$189,414
- Ozempic$101,370
- RYBELSUS$45,436
- JARDIANCE$40,865
- BAQSIMI$21,059
- FARXIGA$18,373
- Tresiba$17,006
- Xultophy 100/3.6$12,969
- SOLIQUA 100/33$10,360
- TOUJEO$7,552
- STEGLATRO$5,513
- Non-Covered$4,592
- UNITY DIABETES MANAGEMENT SYSTEM$2,600
- TEPEZZA$2,200
- Korlym$227
- Abre$159
- Minimed 670G System$129
- t:slim X2 Insulin Pump with Control-IQ$117
- MINIMED 780G$106
How this compares
$887,550 in reported general payments places this provider in the 95th percentile of 804 endocrinology, diabetes & metabolism providers in New York.
See all endocrinology, diabetes & metabolism providers in New York →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 494 | $580,251 |
| TrulicityDulaglutide | 179 | $258,440 |
| MounjaroTirzepatide | 197 | $212,489 |
| JardianceEmpagliflozin | 181 | $179,302 |
| SomavertPegvisomant | 11 | $92,285 |
| Tresiba Flextouch U-200Insulin Degludec | 34 | $46,694 |
| FarxigaDapagliflozin Propanediol | 39 | $41,702 |
| RybelsusSemaglutide | 22 | $37,420 |
| Tresiba Flextouch U-100Insulin Degludec | 38 | $35,697 |
| JanuviaSitagliptin Phosphate | 31 | $33,442 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 189 | $27,444 |
| Humalog Kwikpen U-100Insulin Lispro | 86 | $26,413 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 20 | $22,399 |
| Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/7 | 14 | $22,271 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 49 | $21,456 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus, Novolog | $186,632 | $622,489537 claims |
| Lilly USA, LLCTrulicity, Mounjaro, Humalog | $619,967 | $475,470395 claims |
| Boehringer IngelheimJardiance | $6,885 | $179,302181 claims |
| AstraZenecaFarxiga | $19,132 | $41,70239 claims |
| MerckJanuvia | $5,578 | $33,44231 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 804 endocrinology, diabetes & metabolism providers in New York.
Other endocrinology, diabetes & metabolism in Buffalo
- Erlin MarteBuffalo$570K
- Paresh DandonaBuffalo$109K
- Katherine FrachettiBuffalo$69K
- Robert BuschAlbany$2.7M
- Michael ShanikSmithtown$1.2M
- Vinay KapoorManhasset$820K
- John BilezikianNew York$809K
- Barbara HirschManhasset$746K
- Martin GrajowerBronx$713K
- Anastasios ManessisNew York$656K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.